Track 10: Challenges in Rare Diseases Treatment


There are around 7,000 rare diseases, which from a regulatory outlook are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Orphan drugs are medicinal products envisioned for diagnosis, prevention, and treatment of life-threatening rare diseases. They are "orphans" because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions.



 


    Related Conference of Track 10: Challenges in Rare Diseases Treatment

    November 19-19, 2021

    11th European Epidemiology and Public Health Congress

    Paris, France
    December 01-01, 2021

    4th International Conference on Tropical and Infectious Diseases

    Amsterdam, Netherlands
    February 07-08, 2022

    9th International Congress on Infectious Diseases

    Aberdeen, UK
    March 09-10, 2022

    VIROLOGY CONFERENCE-INFE-2022

    Geneva, Switzerland
    April 25-26, 2022

    4th World Congress on Advancements in Tuberculosis and Lung Diseases

    Singapore City, Singapore
    June 24-25, 2022

    14th Euro-Global Conference on Infectious Diseases

    Berlin, Aland Islands

    Track 10: Challenges in Rare Diseases Treatment Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in